OREXIGEN reports positive 24-week results for Contrave phase III obesity treatment study
Rationally designed combination product achieves greater weight loss than placebo with no indication of reaching a plateau
San Diego, CA, September 26, 2006 -- OREXIGENTM Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, today announced that top line results for the company's lead obesity compound, ContraveTM, demonstrated significant advantages in weight loss in a 24-week multi-center, placebo-controlled phase III trial; the trial will continue unblinded for an additional 24 weeks.
Contrave is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, with one of several different doses of naltrexone, an opioid antagonist used to treat various addictive disorders. The bupropion/naltrexone combination is based on the company's underlying research into the brain's regulation of appetite and energy expenditure, which suggests that combining these two central nervous system drugs may improve the ability to initiate weight loss, and importantly, to continue weight loss by blocking the body's attempts to compensate for weight loss during the treatment. The trial is testing three different dosages of naltrexone combined with the same dosage of bupropion. In what may become the preferred dose pairing based on performance and tolerability, patients completing the 24-week trial using Contrave experienced on average an excess of 7% weight loss from baseline compared to approximately 1% weight loss from baseline on average for patients using the placebo. In addition, the Contrave combination outperformed either naltrexone or bupropion given alone, and the Contrave-associated weight loss trajectory showed no indication of reaching a plateau at the conclusion of 24 weeks of blinded therapy. These findings for Contrave are consistent with an earlier phase II proof of concept study presented at the annual meeting of the American Diabetes Association in June.
"These clinical findings are indicative of a therapeutic synergy when combining naltrexone with bupropion for weight loss. We believe Contrave represents a unique approach to successful long-term weight loss with a very acceptable safety profile," said Gary Tollefson, M.D., Ph.D., OREXIGEN president and CEO. "Contrave is designed to activate a hypothalmic center in the brain associated with reduced appetite, while blocking beta-endorphin, which may be responsible for limiting weight loss. We are also studying the effects of Contrave on related central pathways associated with the rewarding nature of select high calorie foods. OREXIGEN is developing Contrave to provide a steady, manageable weight loss over time. We are also developing a second compound, EXCALIATM, which is designed to provide a more pronounced weight loss trajectory and which is presently being evaluated in a large, double-blinded, phase IIb clinical trial."
The Contrave phase III trial involves more than 250 patients at 14 clinical sites, and was blinded for the first 24 weeks. A second 24 weeks of open-label treatment is currently underway. The three doses of naltrexone were selected based on OREXIGEN's innovative use of Positron Emission Tomography (PET) imaging of the opioid receptors in the human brain.
- Patients completing the 24-week trial who received Contrave with the highest test dose of naltrexone lost an average of 7.52% weight from baseline as compared to an average of 1.03% weight loss from baseline experienced by patients using the placebo. This treatment group also was more likely to have experienced nausea early in the course of their treatment.
- Patients completing the 24-week trial and receiving Contrave with the middle dose of naltrexone, the dose previously mentioned as a possible preferred dose, lost on average an excess of 7% weight from baseline, suggesting that this middle dose provides the best combination of tolerability and efficacy.
- Patients completing the 24-week trial and receiving Contrave with the lowest dose of naltrexone also experienced weight loss with improved tolerability.
Dr. Tollefson continued: "As we review these 24-week findings we believe it is important to continue evaluating Contrave dosing in order to identify those formulations with the greatest clinical benefit coupled with a patient and regulatory view on an acceptable side effect profile."
ABOUT OREXIGEN THERAPEUTICS
OREXIGENTM Therapeutics, Inc. is a privately-held clinical-stage neuroscience company in San Diego, California developing novel strategic approaches to the treatment of obesity. OREXIGEN leverages its proprietary science to design and screen two-drug combinations that work together in the central nervous system to enhance satiety, diminish appetite, improve energy expenditure and minimize the body's efforts to compensate for weight loss. OREXIGEN has two lead compounds in clinical trials, ContraveTM (phase III) and ExcaliaTM (phase IIb), along with a pipeline of earlier stage drug combinations now being tested. Each acts on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. By targeting different groups of neurons OREXIGEN is working to develop compounds that each can achieve a different weight loss profile, providing rapid weight loss where required (Excalia) or emphasizing steady, sustainable weight loss where preferred (Contrave). More information about the company and its programs is available at www.orexigen.com.
OREXIGEN cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding the efficacy and safety of ContraveTM and the potential to obtain regulatory approval for, and effectively treat obesity with, any of OREXIGEN's product candidates. The inclusion of forward-looking statements should not be regarded as a representation by OREXIGEN that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in OREXIGEN's business, including, without limitation: the progress and timing of OREXIGEN's clinical trials, including the potential to replicate in pending and future trials the results described in this press release for ContraveTM; the potential for ContraveTM to receive regulatory approval on a timely basis or at all; the market potential for obesity, and OREXIGEN's ability to compete in the obesity market; and the scope and validity of patent protection for OREXIGEN's product candidates. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and OREXIGEN undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.